Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations and Living at Home
Brief Summary: Aging is often associated with multiple chronic conditions conducting increased consumption of drugs. Drug therapy is necessary for the treatment of many diseases. However, misuse of drugs, particularly linked to the potentially inappropriate prescribing and polypharmacy, increases the iatrogenic risks and can lead to adverse events such as falls, cognitive decline, increased use to the health system: hospital admissions, emergency room visits, and institutionalization. These problems are common since about 20% of emergency room use in elderly patients due to an adverse event related to drugs. Nearly 28% of adverse events related to drug prescriptions could be avoided.

Interventions to optimize drug therapy showed a reduction in the number of potentially inappropriate medications, but their impact on health, has rarely been evaluated. If an association with death has been established, the link with the loss of functional autonomy, which leads to reduced quality of life and significant cost of care, has not been investigated. The evolution towards functional disabilities, frequent with aging has many causes, among which some could be prevented. The optimization of drug prescriptions could thereby delay or prevent the loss of functional autonomy by reducing the risk of adverse events, such as falls or cognitive decline and improving the management of chronic diseases. Our hypothesis is that an optimization program of the drug prescribing may slow progression to functional dependence. To assess the effect of the optimization program of drug prescribing on the level of functional autonomy, a multicenter Randomized Controlled Trial will be conducted in geriatric and memory consultations.

Expected results The implementation of the "OPTIM" program should enable optimization of drug prescribing in elderly patients and therefore slow or prevent progression to addiction. It should also help to develop and strengthen collaboration and communication between the team of geriatric consultation, the clinician pharmacist and referring physicians in town (private practice). In addition, pharmaceutical notice sent to referring physicians should help raise awareness of the prescription of drugs in these patients.


Options:
A: Arm Label: standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensified standard care; Type: OTHER; Interventions: Other: Pharmaceutical Care Service | Intervention Type: OTHER; Name: Pharmaceutical Care Service; Assigned to Arm(s): Intensified standard care
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multidisciplinary treatment | Intervention Type: BEHAVIORAL; Name: multidisciplinary treatment; Assigned to Arm(s): Pharmacist intervention
C: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary collaboration structure | Intervention Type: OTHER; Name: Interdisciplinary collaboration structure; Assigned to Arm(s): Intervention
D: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing

Answer: D